Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eurand S.p.A. |
---|---|
Information provided by: | Eurand S.p.A. |
ClinicalTrials.gov Identifier: | NCT00297167 |
The primary efficacy objective of this study is to compare the coefficient of fat absorption (CFA) following oral administration of Eurand PEP capsules or placebo in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI).
Condition | Intervention | Phase |
---|---|---|
Cystic Fibrosis Exocrine Pancreatic Insufficiency |
Drug: Eurand PEP Capsules |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency |
Estimated Enrollment: | 30 |
Study Start Date: | February 2006 |
Ages Eligible for Study: | 7 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Key Exclusion Criteria:
United States, Texas | |
University of Texas Health Center at Tyler | |
Tyler, Texas, United States, 75708 |
Principal Investigator: | Rodolfo Amaro Galvez, MD | University of Texas Health Center at Tyler |
Study ID Numbers: | EUR-1008-M |
Study First Received: | February 27, 2006 |
Last Updated: | September 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00297167 |
Health Authority: | United States: Food and Drug Administration |
CF Cystic Fibrosis EPI Exocrine Pancreatic Insufficiency |
Pancreatic Enzyme PEP EPI |
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis Fibrosis |
Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases Cystic fibrosis Exocrine Pancreatic Insufficiency |
Pathologic Processes |